Ke Xu

Dr. Ke Xu earned his first degree in Microbiology in 1989 from School of Life Sciences in Nankai University (China), and his Ph.D. in Cell and Molecular Biology in 2001 from University of Essex (UK). He completed his postdoctoral training at the Institute of Cancer Research (UK), studying on the induction of leukemia cell apoptosis and differentiation. Dr. Ke Xu carried out his research fellowship at Imperial College London (UK), investigating gene targeting and lung cancer. He joined the Tianjin Lung Cancer Institute of Tianjin Medical University General Hospital (China) in 2007 as a professor to establish an independent research group, studying the molecular mechanism of metastasis and chemoresistance of lung cancer. He also develops novel chemical compounds to interfere with key cancer promoting pathways. Dr. Ke Xu is an active member of American Association of Cancer Research, American Society for Cell Biology, Chinese Anti-Cancer Association and Chinese Pharmaceutical Association.

2books edited

Latest work with IntechOpen by Ke Xu

The development of technologies that allow targeting of specific cells has progressed substantially in recent years for several types of vectors, particularly viral vectors, which have been used in 70% of gene therapy clinical trials. Particular viruses have been selected as gene delivery vehicles because of their capacities to carry foreign genes and their ability to efficiently deliver these genes associated with efficient gene expression. This book is designed to present the most recent advances in viral gene therapy

Go to the book